Showing results (421-430 of 438) with videos related to

Sort By:
Pageof 44
Lancet (London, England)|March 23, 2017
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trialE Magnus Ohman, Matthew T Roe, P Gabriel Steg, et al.
JACC. Cardiovascular Interventions|July 9, 2021
Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCIDominick J Angiolillo, Davide Cao, Usman Baber, et al.
The New England Journal of Medicine|November 10, 2025
Evolocumab in Patients without a Previous Myocardial Infarction or StrokeErin A Bohula, Nicholas A Marston, Ajay K Bhatia, et al.
European Heart Journal|August 23, 2021
Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKDGiulio G Stefanini, Carlo Briguori, Davide Cao, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|March 24, 2022
Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKDPayam Dehghani, Davide Cao, Usman Baber, et al.
Journal of the American College of Cardiology|August 17, 2023
Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary InterventionsGuiomar Mendieta, Shamir Mehta, Usman Baber, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|August 18, 2022
Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG studyGennaro Sardella, Frans J Beerkens, George Dangas, et al.
JACC. Cardiovascular Interventions|October 25, 2023
Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary InterventionDominick J Angiolillo, Davide Cao, Samantha Sartori, et al.
Circulation|May 19, 2026
Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior MI: Results From the VESALIUS-CV TrialBrian A Bergmark, Erin A Bohula, Nicholas A Marston, et al.
JACC. Cardiovascular Interventions|January 16, 2022
Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT SubstudyMauro Chiarito, Usman Baber, Davide Cao, et al.
Pageof 44